N-diphenylacetoxysuccinimide | 226218-61-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-diphenylacetoxysuccinimide
• 英文别名: succinimidyl 2,2-diphenylacetate；succinimidyl diphenylacetate；2,5-Dioxopyrrolidin-1-yl 2,2-diphenylacetate；(2,5-dioxopyrrolidin-1-yl) 2,2-diphenylacetate
• CAS: 226218-61-7
• 化学式: C₁₈H₁₅NO₄
• mdl: MFCD00395512
• 分子量: 309.321
• InChiKey: SXBXGURRDRCIDJ-UHFFFAOYSA-N

物化性质

• 熔点：
  120-122 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• 沸点：
  460.5±55.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  63.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-diphenylacetoxysuccinimide 在 palladium on activated charcoal 、 甲酸铵 、 sodium carbonate 、 二乙胺 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 100.5h， 生成 (R)-N-(4-tert-butoxybenzyl)-Nω-tert-butoxycarbonyl-Nα-(2,2-diphenylacetyl)argininamide
  参考文献：
  名称：

  Synthesis and Binding Affinity of Fluorine Containing NG-acyl and -sulfonyl BIBP3226 Derivatives: Ligands for the NPY Y1 Receptor

  摘要：

  神经肽 Y（NPY）受体在多种肿瘤中含量丰富，因此是肿瘤成像和治疗的分子靶点，尤其是通过使用放射性标记分子。我们制备了 NPY 受体拮抗剂 BIBP3226 的 NG 取代衍生物，旨在改善其当前的可用性，并将正电子发射放射性同位素用于正电子发射断层扫描（PET）放射性药物的开发。BIBP3226 衍生物的制备分为七个步骤，同时保留了至关重要的氨基酸手性。酰基衍生物保留了可接受的配体结合力，而磺酰衍生物则几乎完全丧失了结合亲和力。

  DOI：

  10.1071/ch15569
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 2,2-二苯基乙酸 在 N,N'-二环己基碳二亚胺 作用下， 以 乙腈 为溶剂， 反应 1.0h， 以88%的产率得到N-diphenylacetoxysuccinimide
  参考文献：
  名称：

  通过碳二亚胺偶联对醇和酚进行选择性酯化。

  摘要：

  在用碳二亚胺处理后能够形成烯酮中间体的羧酸的酯化反应可在缺乏强吸电子基团的酚存在下对醇进行选择性酰化。可以通过添加催化量的酸来逆转涉及高酸性酚的酰化反应的选择性。发现其他羧酸的酯化反应通过对称酸酐的形成进行，并提供相反的化学选择性。在这两种情况下，取代酚的相对酰化速率均与反应机理一致，该机理涉及酚盐阴离子攻击亲电子中间体（例如乙烯酮和对称酸酐），而碳二亚胺既用作活化剂，又用作碱性催化剂。

  DOI：

  10.1039/b312559a

文献信息

• Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools
  作者：Max Keller、Daniela Erdmann、Nathalie Pop、Nikola Pluym、Shangjun Teng、Günther Bernhardt、Armin Buschauer

  DOI：10.1016/j.bmc.2011.03.045

  日期：2011.5

  Fluorescently labelled NPY Y1 receptor (Y1R) ligands were synthesized by connecting pyrylium and cyanine dyes with the argininamide-type Y1R antagonist core structure by linkers, covering a wide variety in length and chemical nature, attached to the guanidine group. The most promising fluorescent probes had Y1R affinities (radioligand binding) and antagonistic activities (calcium assay) in the one-

  荧光标记的NPY Y 1受体（Y 1 R）配体是通过将吡啶鎓和花青染料与精氨酸酰胺型Y 1 R拮抗剂核心结构通过连接子连接起来而合成的，所述连接子覆盖了连接在胍基上的各种长度和化学性质。最有前途的荧光探针的Y 1 R亲和力（放射性配体结合）和拮抗活性（钙测定）在1到2位数纳摩尔范围内。这些化合物在测定条件下稳定且适合检测Y 1通过共聚焦显微镜检查活细胞中的Rs。为了通过将发射转移到近红外来提高信噪比，合成了一种新的苯并噻唑鎓型荧光花青染料（UR-DE99），并通过一个氨基甲酰基连接剂连接到母体拮抗剂上，生成了高强度的UR-MK131。强效荧光Y 1 R探针，也已成功应用于流式细胞仪中。
• Selective esterifications of alcohols and phenols through carbodiimide couplingsElectronic supplementary information (ESI) available: the characterization of new compounds and literature references for known compounds. See http://www.rsc.org/suppdata/ob/b3/b312559a/
  作者：Rimma Shelkov、Moshe Nahmany、Artem Melman

  DOI：10.1039/b312559a

  日期：——

  Esterification of carboxylic acids capable of forming ketene intermediates upon treatment with carbodiimides permits the selective acylation of alcohols in the presence of phenols lacking strong electron-withdrawing groups. The selectivity of acylations involving highly acidic phenols could be reversed through the addition of catalytic amount of acid. Esterification of other carboxylic acids was found

  在用碳二亚胺处理后能够形成烯酮中间体的羧酸的酯化反应可在缺乏强吸电子基团的酚存在下对醇进行选择性酰化。可以通过添加催化量的酸来逆转涉及高酸性酚的酰化反应的选择性。发现其他羧酸的酯化反应通过对称酸酐的形成进行，并提供相反的化学选择性。在这两种情况下，取代酚的相对酰化速率均与反应机理一致，该机理涉及酚盐阴离子攻击亲电子中间体（例如乙烯酮和对称酸酐），而碳二亚胺既用作活化剂，又用作碱性催化剂。
• Guanidine−Acylguanidine Bioisosteric Approach in the Design of Radioligands: Synthesis of a Tritium-Labeled <i>N</i>^G-Propionylargininamide ([³H]-UR-MK114) as a Highly Potent and Selective Neuropeptide Y Y₁ Receptor Antagonist
  作者：Max Keller、Nathalie Pop、Christoph Hutzler、Annette G. Beck-Sickinger、Günther Bernhardt、Armin Buschauer

  DOI：10.1021/jm801018u

  日期：2008.12.25

  tritium-labeled NPY Y(1) receptor (Y(1)R) antagonist (K(B): 0.8 nM, calcium assay, HEL cells) derived from the (R)-argininamide BIBP 3226, is reported. The radioligand binds with high affinity (K(D), saturation: 1.2 nM, kinetic experiments: 1.1 nM, SK-N-MC cells) and selectivity for Y(1)R over Y(2), Y(4), and Y(5) receptors. The title compound is a useful pharmacological tool for the determination of Y(1)R ligand

  （R）-Nα-（2,2-二苯基乙酰基）-N-（4-羟基苄基）-N（ω）-（[2,3-（3）H]-丙酰基）精氨酰胺的合成与表征（[（3）H] -UR-MK114），一种易于获得的tri标记的NPY Y（1）受体（Y（1）R）拮抗剂（K（B）：0.8 nM，钙测定，HEL细胞），其衍生自报道了（R）-精氨酰胺BIBP 3226。放射性配体具有高亲和力（K（D），饱和度：1.2 nM，动力学实验：1.1 nM，SK-N-MC细胞）结合，并且对Y（1）R的选择性高于Y（2），Y（4）和Y（5）受体。标题化合物是用于确定Y（1）R配体亲和力，定量Y（1）R结合位点和放射自显影的有用药理学工具。
• NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN
  申请人：RIKEN

  公开号：US20150119254A1

  公开（公告）日：2015-04-30

  An object of the present invention is to develop and provide a method for efficiently producing a nucleic acid aptamer, particularly, a DNA aptamer, having higher specificity and binding activity against a target substance than those of nucleic acid aptamers obtained by conventional methods. The present invention provides a transcribable or replicable nucleic acid aptamer comprising a natural nucleotide and a non-natural nucleotide having an artificial base-pairable artificial base. The present invention also provides a method for sequencing a non-natural nucleotide-containing single-stranded nucleic acid molecule selected from a single-stranded nucleic acid library.

  本发明的目的是开发并提供一种有效生产核酸适配体的方法，特别是DNA适配体，其对目标物质具有比传统方法获得的核酸适配体更高的特异性和结合活性。本发明提供了一种可转录或可复制的核酸适配体，其包含一种自然核苷酸和一种非自然核苷酸，后者具有人工可配对人造碱基。本发明还提供了一种从单链核酸库中选择的含有非自然核苷酸的单链核酸分子的测序方法。
• Dimeric argininamide-type neuropeptide Y receptor antagonists: Chiral discrimination between Y1 and Y4 receptors
  作者：Max Keller、Melanie Kaske、Tobias Holzammer、Günther Bernhardt、Armin Buschauer

  DOI：10.1016/j.bmc.2013.08.065

  日期：2013.11

  The structurally related peptides neuropeptide Y (NPY), peptide YY (PYY) and pancreatic polypeptide (PP) are endogenous agonists of the NPY receptor (YR) family, which in humans comprises four functionally expressed subtypes, designated Y1R, Y2R, Y4R and Y5R. Nonpeptide antagonists with high affinity and selectivity have been described for the Y1R, Y2R and Y5R, but such compounds are still lacking for the Y4R. In this work, the structures of the high affinity selective (R)-argininamide-type Y1R antagonists BIBP3226 and BIBO3304 were linked via the guanidine or urea moieties to give homo-dimeric argininamides with linker lengths ranging from 31 to 41 atoms. Interestingly, the twin compounds proved to be by far less selective for the Y1R than the R-configured monovalent parent compounds. The decrease in selectivity ratio was most pronounced for Y1R versus Y4R subtype, resulting in comparable affinities of bivalent ligands for Y1R and Y4R (e.g. UR-MK177 ((R, R)-49): K-i = 230 nM (Y1R) and 290 nM (Y4R)). With a Ki value of 130 nM and a K-b value of 20 nM, UR-MK188 ((R,R)-51) was superior to all Y4R antagonists known to date. The S, S-configured optical antipodes of UR-MK177 and UR-MK188 (UR-MEK381 ((S, S)-49) and UR-MEK388 ((S,S)-51)) were synthesized to investigate the stereochemical discrimination by the different receptor subtypes. Whereas preference for R, R-configured argininamides was characteristic of the Y1R, stereochemical discrimination by the Y4R was not observed. This may pave the way to selective Y4R antagonists. (C) 2013 Elsevier Ltd. All rights reserved.